Wealth Enhancement Advisory Services LLC Purchases Shares of 3,615 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Wealth Enhancement Advisory Services LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,615 shares of the medical equipment provider's stock, valued at approximately $290,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LNTH. UMB Bank n.a. boosted its stake in Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 247 shares during the last quarter. GAMMA Investing LLC increased its holdings in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 208 shares during the period. Principal Securities Inc. purchased a new position in Lantheus during the 4th quarter worth $28,000. Fidelis Capital Partners LLC purchased a new position in Lantheus during the 1st quarter worth $34,000. Finally, FinTrust Capital Advisors LLC increased its holdings in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 232 shares during the period. 99.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on LNTH. Leerink Partners raised their price objective on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. JMP Securities cut their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Friday, May 3rd. Finally, Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $119.00.

Lantheus Stock Performance

Shares of LNTH stock traded up $0.15 during mid-day trading on Monday, hitting $107.31. 617,490 shares of the stock were exchanged, compared to its average volume of 1,056,229. The stock's fifty day simple moving average is $97.48 and its two-hundred day simple moving average is $78.10. The stock has a market capitalization of $7.44 billion, a price-to-earnings ratio of 16.38 and a beta of 0.51. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.55 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the business earned $1.40 EPS. Lantheus's revenue for the quarter was up 22.5% on a year-over-year basis. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.46 EPS for the current year.

Insiders Place Their Bets

In related news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the business's stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the transaction, the director now owns 23,340 shares in the company, valued at approximately $1,848,294.60. The disclosure for this sale can be found here. In the last three months, insiders sold 72,439 shares of company stock valued at $6,432,198. Company insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.